3 top picks in global healthcare |
-- |
29/09/2020
Text size 
| 
|
| Tweet |  |
<p><strong>Lex Hall:</strong> Hi, I'm Lex Hall for Morningstar. Michael Li is the Co-Manager of the Healthcare Impact Fund at American Century Investments. And today, we're going to talk about three key holdings in the fund and why he likes them.</p>
<p>Michael, welcome to Morningstar.</p>
<p><strong>Michael Li: </strong>Hello, Lex. Thank you for having me.</p>
<p><strong>Hall: </strong>My pleasure. Now, let's talk about three key holdings in your fund. The first name on the list is Biogen. Tell us about your interest in Biogen: what it does and why you see so much promise in it.</p>
<p><strong>Li: </strong>Sure, Lex. So, Biogen is a biotech company based in Boston, Massachusetts in the US and the company is a leader in the neuroscience area. So, they have multiple treatments for multiple sclerosis. At the same time, they have invested in the neurodegenerative diseases for many years. So, they have multiple programs in that particular area. So, as we all know, Alzheimer's is one of the major diseases that affects millions of people around the globe, and we don't have really much of an effective treatment at this point.</p>
<p>So, through its innovation, they have one drug that shows good efficacy in treating the Alzheimer's patients to really improve the decline in the cognitive ability for those patients; and the drug is an antibody targeting beta amyloid, and the name of the drug is aducanumab. So, they right now have the drug application with the FDA. And so, we're still just waiting for the FDA approval. And if approved by the agency, it could become really one of the first disease-modifying therapies for Alzheimer's patients. So, in our opinion, like if they can get that on the market, it can create potentially a huge impact on the society through the unmet medical needs.</p>
<p><strong>Hall: </strong>And how long have you held Biogen for, Michael?</p>
<p><strong>Li: </strong>So, we invested in Biogen since the inception of the strategy.</p>
<p><strong>Hall: </strong>OK. So, 2018…</p>
<p><strong>Li: </strong>In late 2018, correct.</p>
<p><strong>Hall: </strong>OK. The second name on your list is one that we've heard a lot about this year with covid-19. It's Gilead Sciences. Again, how long have you been exposed to it and why do you hold it in such a steam?</p>
<p><strong>Li: </strong>Yeah. So, invested in the company in late 2018 when we started the strategy. And the one thing I want to remind people is that this is a very low turnover strategy for us. We are really trying to identify the best companies out there and really hold them for a long time.</p>
<p>So, this is a great example to really illustrate the combination of impact with financial returns. So, Gilead Sciences is a biotech company based in California. It's a leader in antivirus treatment. So, for example, that includes HIV, HCV, and more than 80 per cent of the HIV patients treated used one of their therapies or drugs.</p>
<p>So, through its innovation and R&D work it has quickly developed an effective treatment for severe covid-19 patients. So, as we go through the pandemic today, this is really the only approved therapy right now by the FDA to treat those patients, and it offers some of the last resort for those patients. And overall, this overall effort is creating a huge impact on society because given what we are going through and that we do think that this is a very good example of how we can generate financial returns while also creating the social impact that we're looking for.</p>
<p><strong>Hall: </strong>OK. And the final name on your list of three today Michael is Teladoc. Tell us about Teladoc.</p>
<p><strong>Li: </strong>Yeah. So, Teladoc is relatively a smaller company. It's what I call the leader in telemedicine. So, what they do is they provide virtual care or virtual access to healthcare for patients who either have limited access or have worries to go to see a doctor. So, for example, as we are in the pandemic today, a lot of the patients are afraid to go to the hospitals or the clinics to see their physicians face to face. So, through Teladoc, they can schedule a virtual session with the doctor and still be taken care of. So, that is a really sort of effective way of how people can get access to medicine. So, for example, last year they treated over 2 million visits and this year they multiplied that by a few times because of the demand for telemedicine certainly skyrocketed with the pandemic.</p>
<p>The second thing that's really interesting about Teladoc is—or the virtual visits is—it lowers cost as well. So, for example, if patients go to see a doctor through Teladoc's platform, they pay $40, $50 per visit. But if they go actually to see a doctor of face-to-face, that's going to cost close to $100 in the US. They not only transformed the way how healthcare can be delivered, also they are lowering the overall healthcare cost through very effective way.</p>
<p><strong>Hall: </strong>I'm curious to know when you picked that stock up, did you pick it up at the beginning of this year or since inception or…?</p>
<p><strong>Li: </strong>No, we really invested in the company since the inception. So, we have paid attention to this space for a long time and we always felt that this is a very innovative company that's leading the space, and this could potentially really transform the way. So, we really invested in it very early on.</p>
<p><strong>Hall: </strong>And it sounds like the Zoom of healthcare, if you like. How has it been performing?</p>
<p><strong>Li: </strong>Very much so. It has done very well.</p>
<p><strong>Hall: </strong>All right. Well, that's some fascinating insights there. That's Biogen, Gilead Sciences, and Teladoc. Michael Li from American Century Investments, thanks very much for your insights today.</p>
<p><strong>Li: </strong>Thank you, Lex.</p>
<p> </p>
<p><strong>Hall: </strong>I'm Lex Hall for Morningstar. Thanks for watching.</p>
AMP: difficulties now, but dividends later27/11/2020 The 171-year-old wealth manager has had its scandals but there's merit to its turnaround strategy and the quality of its other assets, says Morningstar's Shaun Ler.
'Be careful using buy now pay later'27/11/2020 BNPL products such as Zip Co help boost consumer spending but they come with risks and are overvalued, says Morningstar analyst Shaun Ler.
Hamish Douglass: Winners and losers in the covid era26/11/2020 The Magellan co-founder argues the ecommerce acceleration is here to stay and ponders the effect it will have on other sectors such as travel and commercial real estate.
A 'wonderful hunting ground'25/11/2020 Greg Dean of Cambridge Global Asset Management explains why the consumer services sector has yielded healthy returns.
Hamish Douglass and big tech25/11/2020 Magellan's co-founder explains which tech behemoth the Magellan Global Fund no longer owns, why one was too tricky to value, and why regulation is no threat.
Hamish Douglass: 'We're lucky this pandemic hit when it did'24/11/2020 Magellan's co-founder on why 2020 resembles 2000 and why covid-19 is a dry run for something that could be much worse without proper planning.
Should you beef up your exposure to meat processors?23/11/2020 Their shares have gotten hammered this year. Are they opportunities or value traps?
What is the Morningstar ESG Commitment level?20/11/2020 Our new rating highlights the degree to which a fund or asset manager considers environmental, social, and governance issues.
What's driving the flows into ESG funds19/11/2020 Morningstar's Grant Kennaway explains why sustainable funds are increasingly popular and why they're performing well.
Too much upside baked into Bunnings: Morningstar17/11/2020 Morningstar director of equity research Johannes Faul looks at home improvement retailer Bunnings.
What is ESG?16/11/2020 From climate change to workers' rights, ESG is a big part of the investing world. We're at the Morningstar whiteboard board to explain what it means and why it matters.
"I'm still cautious": Peter Warnes' best ideas for income investors12/11/2020 We're not out of the woods yet, says our head of equity research, as he looks for safety in businesses we can't live without and shies away from the banks.
Is it time to get exposure to China?11/11/2020 Perhaps it is time to have exposure to this economic powerhouse and its 1.4 billion population, says Morningstar's Peter Warnes.
Tapping into the contactless spending boom10/11/2020 What happens when you buy something when your bank card? Morningstar analyst Niklas Kammer explains which companies are benefiting from your transaction.
Can luxury stocks recover from covid?09/11/2020 With travel bans and economic lockdowns, the luxury sector has been hit hard in 2020. But there are still opportunities, says Morningstar analyst Jelena Sokolova.
US election scenarios and what they mean for investors05/11/2020 A discussion of taxes, stimulus, regulation, and the likely market reaction as results from the 2020 poll come in.
Don't try to time elections03/11/2020 Why you should resist the urge to make predictions when there's a disconnect between the economy and security prices.
3 names on the alternative protein shelf02/11/2020 Etoro analyst Josh Gilbert shares his thoughts on Beyond Meat and two other companies making inroads into the plant-based meat sector.
Hamish Douglass: I'd be super surprised if Trump won30/10/2020 The Magellan rainmaker explains why he doubts the Republican leader will prevail and why investors should brace for volatility—and ignore it.
Gauging the appetite for alternative protein29/10/2020 The market for plant-based meat is worth $14bn today and is expected to grow massively, says eToro's Josh Gilbert.
Browsing the opportunities aisle in retailing28/10/2020 Morningstar equity analyst Johannes Faul explores the flipside to the surge in growth in online sales.
3 top Asian picks on Longlead's radar22/10/2020 China and Hong Kong have been a happy hunting ground, says Longlead Capital Partners' co-founder Andrew West, who singles out tech, pharmaceuticals and power tools.
3 undervalued travel stocks we like22/10/2020 These names stand to benefit from a resumption of leisure travel - and are all trading below our fair value estimates.
3 reasons to like bonds20/10/2020 Morningstar's Mark Preskett looks at three reasons why bonds are an important tool in your investment portfolio.
The monopoly asset that could boost Link19/10/2020 A bigger stake in the online conveyancer PEXA could be the key to increasing Link Administration's revenue, says Morningstar's Gareth James.
How Longlead Capital defied the covid plunge16/10/2020 Longlead Capital Partners co-founder Andrew West reveals how his Asia-focused fund managed to make gains during the historic covid-19 sell-off.
Investing basics: why invest in bonds?16/10/2020 The investment board is back with an explainer on why you might invest in bonds.
Retiring during a pandemic13/10/2020 How to handle this decision—even when it is made for you.
3 top picks in sustainability and software12/10/2020 Nick Griffin of Munro Partners reveals why and where he sees opportunities in renewable energy, diagnostics and software.
Investing basics: what's your personal inflation rate?09/10/2020 Take stock of your spending to determine if inflation is an issue for you.
Ant Group IPO: What you need to know09/10/2020 Morningstar analyst Chelsey Tam explains why investors are excited about the flotation of Ant Group and why it's different from Alibaba.
Spotting the winners of tomorrow06/10/2020 Companies that address the growing demand for decarbonisation will have a 20-year growth opportunity, says Nick Griffin of Munro Partners.
An interview with Whitehaven Coal chief Paul Flynn30/09/2020 EXCLUSIVE EXTRACT: Morningstar's Mat Hodge and Lex Hall talk to the CEO of the independent producer and exporter about the company's fortunes and its future.
How to get rich slowly30/09/2020 Slow and steady wins the financial race.
3 top picks in global healthcare29/09/2020 American Century Investments' low-turnover strategy invests in companies developing vaccines, treatments for neuro-cognitive diseases and innovations in telemedicine.
Investing in the healthcare needs of the future25/09/2020 By 2050, almost 20 per cent of the global population will be over 65 and demand for healthcare will climb, says Michael Li of American Century Investments.
Morningstar's Mat Hodge on Rio's fortunes22/09/2020 The destruction of an indigenous cave shelter was unforgiveable but there are other reasons why the iron ore heavyweight is overvalued.
Cannabis: the world in 203021/09/2020 Morningstar equity analyst Kristoffer Inton on the outlook for the seven producers under coverage.
3 top picks for the EV revolution18/09/2020 Morningstar's Seth Goldstein singles out three undervalued stocks that span the entire electric vehicle supply chain.
The 2020 election and your portfolio18/09/2020 The bumps and bruises of election time may tempt you to shift your portfolio strategy.
'The tech rally has gone too far'17/09/2020 UK-based Premier Miton's Simon Evan-Cook says the tech rally of 2020 is reminiscent of the dotcom boom, but inflation could be a bigger threat.
Why EVs will be a common sight on the roads of the future16/09/2020 By 2025, the cost of batteries and manufacturing will fall and EV functionality will improve, says Morningstar's Seth Goldstein.
Using personal data to better estimate retirement savings11/09/2020 Estimating the length of your retirement with personalized information will help you save the correct amount.
2 China stocks we like09/09/2020 Morningstar's Chelsey Tam reveals which stocks and sectors have shone—and which have underwhelmed.
How to be a better investor: episode 328/08/2020 Products, services, what is what in the world of finance—and how to look out for yourself
Where to invest for income24/08/2020 A raft of companies have cut their dividends this year, leaving income investors concerned. But Morningstar's Dan Lefkovitz says there are still plenty of options out there.
DNR Capital's eye for gaming, building supplies and software18/08/2020 DNR Capital's chief investment officer Jamie Nicol profiles some of the top ten holdings in his Australian Equities High Conviction fund.
The trouble on Telstra's horizon17/08/2020 Morningstar's Brian Han explains why he has trimmed his fair value estimate for Australia's dominant telco and the future of its dividend payout.
Finding bargains the market overlooks14/08/2020 DNR Capital's Jamie Nicol reveals how his Australian Equities High Conviction fund finds quality businesses that will endure difficult conditions.
How to be a better investor: episode 213/08/2020 Put your money to work if you're looking for financial freedom.
How to be a better investor: episode 110/08/2020 Learn how to picture your goals so you can better reach them.
3 undervalued names in childcare05/08/2020 Morningstar's Gareth James identifies three sector names trading at attractive discounts in an increasingly 'essential' sector.
Is the 60/40 portfolio dead?05/08/2020 Reports of the strategy's demise are greatly exaggerated, says Morningstar's Christine Benz.
Why you should ignore a fund's yield04/08/2020 Investors may assume a fund's yield to determine how much income it will pay, but it's not always so simple, warns Morningstar analyst Rajesh Yadav.
What are the right bonds for retirees today?03/08/2020 It depends on your expectations and timeframe. Look at bonds as being portfolio stabilisers—sources of cash flow you can draw on when your equities are down, says Christine Benz.
3 top picks in rail, roads and utilities28/07/2020 When utility stocks plunged during the onset of the pandemic Lazard Asset Management's Warryn Robertson knew it was time to jump in.
Infrastructure stocks in the covid era24/07/2020 Lazard Asset Management's Warryn Robertson looks at how the pandemic has affected toll roads and airports and what the future of travel holds.
ESG stocks shine in covid-19 crisis23/07/2020 Morningstar analyst Tancrede Fulop singles out a few companies that have performed well and also led the way in looking after staff.
Stock-picking: Have you got what it takes?21/07/2020 New stock-pickers are prone to lose money. Are the lessons worth the price? We ask Morningstar's Christine Benz.
Why mining stocks aren't yield plays20/07/2020 Elevated iron ore prices have lifted mining company earnings to eye-watering levels but this doesn't make them income stocks, says Morningstar's Mat Hodge.
Commodity stocks riding high, but for how long?17/07/2020 Local miners should deliver stellar fiscal 2020 results but such outperformance is unlikely to last, says Morningstar’s Mat Hodge.
The rise and rise of Amazon17/07/2020 --
Should your portfolio shift when the economy slumps?16/07/2020 How to make some upgrades during this down time.
Will Airbnb IPO or what?16/07/2020 Covid-19 has made the intended public offering impossible, says Morningstar's Andrew Willis.
3 Japanese stock picks15/07/2020 JPMorgan's Nicholas Weindling talks opportunities in Japan and reveals the stock that has been his largest holding for almost a decade
Small cap stocks: 'Inevitably, we see it all end in tears'15/07/2020 The asset class has a habit of outperforming but Morningstar's Ross MacMillan sees signs of a bubble.
A trio of growth stocks13/07/2020 Rachel Winter of UK fund manager Killik & Co talks payments, social media and investing in her monthly stock pick round-up
3 reasons healthcare is showing fit performance09/07/2020 And what we expect to see moving forward.
Same old story: growth beats value07/07/2020 Large growth maintains its supremacy in the Morningstar Style Box during a volatile first half for mutual funds.
Nikko's 3 top Asian picks06/07/2020 Nikko Asset Management's Peter Monson looks for strong sustainable returns and he sees that in Asian stocks that span financial exchanges, computer game makers and condiments suppliers.
How appealing are Asian stocks?02/07/2020 China’s ongoing recovery from COVID-19 presents solid investment opportunities, says Nikko Asset Management.
'Unemployment will be higher, activity lower'01/07/2020 Aviva Investors' Mark Robertson on the 'second wave', the widening gap between the West and China, portfolio protection and how covid has accelerated the tech revolution.
Smartwatches and luxury watches battle for your wrist29/06/2020 Does the rise in smartwatches show that data, not diamonds, are a girl's best friend?
3 top picks in water and waste26/06/2020 They may be 'boring' says Fidelity's Bertrand Lecourt but these names offer solid and long-term returns by delivering essential services.
Tapping opportunities in water and waste25/06/2020 The growing consumption of water and the increased production of waste make these sectors compelling investments, says Fidelity's Bertrand Lecourt.
Dividends: ‘You have to be very active in stock selection’23/06/2020 Yield can still be found among global healthcare, technology and consumer staples despite the dismal dividend outlook, says Janus Henderson’s Jane Shoemake.
Airlie went shopping during COVID sell-off22/06/2020 COVID has given consumers the "fright of their lives" but this fund manager took the opportunity to scoop up bargain bluechips, says portfolio manager Matt Williams.
3 top picks: miner, insurer, fueler19/06/2020 Mineral Resources, Medibank Private and Ampol are among Airlie Fund Management's preferred stocks, says portfolio manager Matt Williams.
Retail bonanza can’t last, warns Morningstar16/06/2020 Investors shouldn’t project the pandemic-driven performance of JB HiFi and Harvey Norman too far into the future.
3 Aussie equities to watch11/06/2020 Lazard Asset Management's Philipp Hofflin explains why mortgage processing, insurance and aluminium production are on his radar.
Are value stocks due for a comeback?10/06/2020 Value investing has massively underperformed growth over the past decade. Christine Benz talks with Alex Bryan about the fundamental case for value.
3 top picks for a covid crisis05/06/2020 Specialist consulting firms and chocolate bars. It's a disparate mix but Ned Bell of Bell Asset Management has good reason for seeing value in these sectors right now.
What the share market is missing04/06/2020 Earnings results will be a rude awakening, says Ned Bell of Bell Asset Management, but there is nevertheless value among some global small- to mid-cap stocks.
The dividend balancing act03/06/2020 Ensure your dividend-paying companies are more than attractive on the surface with these tips from Morningstar Canada's director of investment research, Ian Tam, CFA.
How dividend-paying stocks fit into retiree portfolios01/06/2020 Christine Benz suggests retirees should take a balanced approach to these strategies.
Casino comeback and the uncertainty engulfing Seven West29/05/2020 Most punters would prefer to lose money with their friends in a real casino than gambling online alone in their basement, says Brian Han.
The WFH reality-check for REITs28/05/2020 Working from home means upheaval for office landlords but shopping mall owners are enjoying the end of hibernation, says Morningstar's Brian Han.
An undervalued, wide-moat name in healthcare27/05/2020 Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
5 investing mistakes to avoid20/05/2020 Christine Benz discusses pitfalls investors encounter as they navigate volatility and recovery.
Ugly housing outlook won’t last19/05/2020 Adelaide Brighton, Amcor and Bingo should ride out the housing construction slump with relative ease, says Morningstar’s Grant Slade.
3 stocks set to clean up18/05/2020 The biggest corporate hygiene company you never heard of; Dettol's parent company; and a lab supplier are tipped to benefit post-coronavirus.
Greencape's three top picks13/05/2020 Property listings, software for financial planners and AI machine-learning: Jonathan Koh has scoured the globe for opportunities.
Where to hunt when guidance statements get torn up12/05/2020 Greencape Capital entered the downturn with a cash reserve that has allowed it to snare some essential services companies at bargain prices, says Jonathan Koh.
Investing basics: the hardest decision in investing08/05/2020 When and how should you get back into equity markets after panic selling?
Weighing up Australia’s banks07/05/2020 Bad debts and expected capital raising from three of the big four cloud the outlook for Aussie banks, says Morningstar's Nathan Zaia.
Surprises from Berkshire's annual meeting05/05/2020 Morningstar's Gregg Warren discusses the meeting's cautious tone, Berkshire's lack of buying during the downturn, and unloading the airlines.
Banks will see out corona crisis04/05/2020 Loan defaults, shaky house prices and a dividend pause - it's ugly in the short term but Nathan Zaia has long-term faith in Australia's banks.
What the pandemic means for Berkshire Hathaway30/04/2020 Gregg Warren shares his thoughts on its valuation and more.
Netflix steals the show but for how long?29/04/2020 What happens when the lockdown ends? The streaming giant may need to get some serious growth in international markets to make up for investor expectations.
Unique, but normal: riding out this market crisis27/04/2020 The markets follow patterns. We discuss ways to find your way to the upside of the current environment.